Apellis Pharmaceuticals Inc., in collaboration with Sobi, announced that the marketing applications for EMPAVELI® (pegcetacoplan) are currently under review by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency $(EMA)$. This review pertains to the treatment's use in addressing rare kidney diseases, specifically C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The announcement follows the presentation of new data at the European Renal Association Congress, highlighting sustained efficacy and safety in a Phase 3 study. The companies are hopeful for an FDA decision by the upcoming summer, aiming to quickly make EMPAVELI available to patients with these severe conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。